- Moderna Inc (NASDAQ: MRNA) is experimenting with several potential methods of combating the new COVID-19 virus strain, including:
- The South Africa variant-specific booster candidate at the 50 µg dose level and lower.
- An additional booster shot combining the South Africa-specific vaccine and its existing vaccine in a single vaccine at the 50 µg dose level and lower.
- The third dose of its existing authorized vaccine, as a booster at the 50 µg dose level. Dosing has already begun.
- Evaluate both the combined vaccine and the South Africa-specific as an initial shot for people who haven’t yet been vaccinated, at the 100 µg dose level and lower.
- The company completed manufacturing raw material for a booster shot of its COVID-19 vaccine modified to target the South Africa strain, also known as B.1.351.
- The latest jab, code-named mRNA-1273.351, has been shipped to the US National Institutes of Health for additional study.
- Phase 1 trial will be led and funded by the NIH’s National Institute of Allergy and Infectious Diseases.
- In parallel, the company will be conducting its own clinical studies to support regulatory filings for any booster vaccine or updated primary vaccine.
- Price Action: MRNA is up 4.46% at $151.25 in premarket trading on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.